Effect of rosuvastatin on systemic blood pressure in patients with hypercholesterolemia

Experimental and Clinical Cardiology

Volumn 17, Issue 4, 2012, Pages 221-225

  Seki, Shingo ^a   Hashimoto, Koichi ^a   Taniguchi, Ikuo ^a   Yoshimura, Michihiro ^a   Takeda, Nobuakira ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolemia; Hypertension

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84872811446     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sung BH, Izzo JL Jr, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997;10:592-9.
2. Rosendorff C. Effects of LDL cholesterol on vascular function. J Hum Hypertens 2002;16:S26-8.
3. Chopra V, Choksi PU, Cavusoglu E. Beyond lipid lowering: The anti-hypertensive role of statins. Cardiovasc Drugs Ther 2007;21:161-9.
4. Strazzullo P, Kerry SM, Barbato A, Versiero M, Delia L, Cappuccio FP. Do statins reduce blood pressure?: A meta-analysis of randomized, controlled trials. Hypertension 2007;49:792-8.
5. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins. Results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008;168:721-7.
6. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arteroscler Thromb Vasc Biol 2003;23:729-36.
7. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR trial. JAMA 2007;297:1344-53.
8. Ridker PM, Danielson E, Fonseca FAH, et al. The Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
9. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
10. Ferrier KE, Muhlmann MH, Baguet J P, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. Hypertension 2002;39:1020-5.
11. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005;46:310-5.
12. Kawano H, Yano K. Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment. Circ J 2006;70:1116-21.
13. Baldassarre D, Busnach G, Amato M, Pazzucconi F, Sirtori CR. Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 1999;9:108-17.
14. Mancia G, Parati G, Revera M, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: Evidence from PHYLLIS randomised double blind trial. BMJ 2010;340c.
15. Kuklinska AM, Mroczko B, Musial WJ, et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - an open, pilot study. Blood Press 2010;19:260-6.
16. Susic D, Varagic J, Ahn J. Beneficial pleiotropic vasccular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003;42:1091-7.
17. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:23-30.
18. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
19. Wassmann S, Laufs U, Baumer A, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
20. ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.